Aspen Pharmacare Holdings Ltd - Company Profile
Powered by 
All the sales intelligence you need on Aspen Pharmacare Holdings Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Aspen Pharmacare Holdings Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Aspen Pharmacare Holdings Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Aspen Pharmacare Holdings Ltd (Aspen) is a provider of specialty and generic pharmaceuticals for the treatment of a range of acute and chronic conditions. It focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands. Aspen's products are utilized by patients in various healthcare settings across multiple industries. Its manufacturing capabilities cover a range of product types including oral solid dose, semi-solids, liquids, sterile, biological, personal care products and active pharmaceutical ingredients (APIs). The company operates through a network of 65 established offices in over 50 countries. The company has a presence in Sub-Saharan Africa, South East Asia, Latin America, Eastern Europe, Western Europe and the Commonwealth of Independent States. Aspen is headquartered in Durban, South Africa.
Headquarters
South Africa
Address
Aspen Place, 9 Rydall Vale Park, Douglas Saunders Drive ,La Lucia Ridge, Durban
Website
www.aspenpharma.com
Telephone
27 11 2396100
No of Employees
9,500
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
APN (JNB)
Revenue (2024)
$2.4B
-3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-124.6%
(2024 vs 2023)
Market Cap*
$4.3B
Net Profit Margin (2024)
XYZ
-125.4%
(2024 vs 2023)
* As of and is in US$
Aspen Pharmacare Holdings Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Anti-Depressants | Diprivan |
| Anaesthetic | Emla |
| Analgesics (for Pain Relief) | Fraxiparine |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Stake Sale | In September, the company sold its 11.88% to clients of Coronation Asset Management (Pty) Ltd. |
| 2025 | Corporate Changes/Expansions | In May, the company opened a new headquarters in Riyadh, Saudi Arabia. |
| 2024 | Contracts/Agreements | In October, the company entered into a partnership with PinkDrive NPC to support the financing of a brand-new mobile cancer screening clinic. |
Competitor Comparison
| Key Parameters | Aspen Pharmacare Holdings Ltd | Pfizer Inc | Novartis AG | Teva Pharmaceutical Industries Ltd | Hikma Pharmaceuticals Plc |
|---|---|---|---|---|---|
| Headquarters | South Africa | United States of America | Switzerland | Israel | United Kingdom |
| City | Durban | New York City | Basel | Tel Aviv | London |
| State/Province | - | New York | Basel-Stadt | Tel Aviv | England |
| No. of Employees | 9,500 | 75,000 | 75,267 | 31,173 | 9,603 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Stephen Saad | Chief Executive Officer; Director | Executive Board | 1999 | 62 |
| Sean Capazorio | Chief Financial Officer; Director | Executive Board | 2022 | 61 |
| Kuseni Dlamini | Chairman | Non Executive Board | 2012 | 58 |
| Reginald Haman | Director; Group Chief Corporate Services Officer | Executive Board | 2024 | 52 |
| Raeesa Khan | Director; Secretary | Executive Board | 2024 | 35 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer